OrthoPediatrics Corp. (NASDAQ:KIDS) CEO David R. Bailey Sells 6,620 Shares of Stock

OrthoPediatrics Corp. (NASDAQ:KIDS) CEO David R. Bailey sold 6,620 shares of the stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total transaction of $164,573.20. Following the completion of the transaction, the chief executive officer now owns 319,155 shares of the company’s stock, valued at approximately $7,934,193.30. The trade was a 2.03 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

OrthoPediatrics Stock Up 1.8 %

KIDS stock opened at $25.42 on Wednesday. The company has a debt-to-equity ratio of 0.19, a current ratio of 7.17 and a quick ratio of 3.68. OrthoPediatrics Corp. has a 1-year low of $21.02 and a 1-year high of $35.99. The stock has a market capitalization of $617.38 million, a P/E ratio of -20.67 and a beta of 1.22. The business has a fifty day moving average price of $24.79 and a 200-day moving average price of $25.53.

OrthoPediatrics (NASDAQ:KIDS) last posted its earnings results on Tuesday, March 4th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.04. OrthoPediatrics had a negative net margin of 15.00% and a negative return on equity of 5.78%. The business had revenue of $52.67 million for the quarter, compared to analysts’ expectations of $51.16 million. During the same quarter in the prior year, the business earned ($0.23) EPS. Equities analysts forecast that OrthoPediatrics Corp. will post -0.93 earnings per share for the current fiscal year.

Institutional Investors Weigh In On OrthoPediatrics

A number of hedge funds have recently added to or reduced their stakes in KIDS. Wellington Management Group LLP increased its position in OrthoPediatrics by 16.2% during the third quarter. Wellington Management Group LLP now owns 883,221 shares of the company’s stock valued at $23,944,000 after acquiring an additional 122,846 shares during the last quarter. Barclays PLC boosted its holdings in shares of OrthoPediatrics by 319.3% in the third quarter. Barclays PLC now owns 25,298 shares of the company’s stock worth $686,000 after buying an additional 19,264 shares during the last quarter. Geode Capital Management LLC grew its position in OrthoPediatrics by 2.1% during the third quarter. Geode Capital Management LLC now owns 391,492 shares of the company’s stock valued at $10,615,000 after buying an additional 7,972 shares during the period. Mutual of America Capital Management LLC raised its position in OrthoPediatrics by 195.1% in the third quarter. Mutual of America Capital Management LLC now owns 107,609 shares of the company’s stock worth $2,917,000 after acquiring an additional 71,146 shares during the period. Finally, Centiva Capital LP purchased a new position in shares of OrthoPediatrics during the 3rd quarter worth $319,000. 69.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. Stifel Nicolaus lowered their target price on shares of OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, March 5th. Truist Financial cut their target price on OrthoPediatrics from $28.00 to $25.00 and set a “hold” rating on the stock in a research note on Wednesday, December 18th. Finally, Needham & Company LLC reissued a “buy” rating and set a $42.00 price objective on shares of OrthoPediatrics in a research report on Wednesday, March 5th.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.